Meeting
2021 ASCO Annual Meeting
Final survival results from a multicenter, randomized phase II trial of intravenous paclitaxel plus FOLFOX (ivPOF) and/or intraperitoneal paclitaxel plus FOLFOX (ipPOF) versus mFOLFOX6 as first-line treatment of advanced gastric cancer (AGC): SYLT/FNF 004.
Authors
Shen Zhao
Gastrointestinal Medical Oncology, Fujian Cancer Hospital, Fuzhou, China
Shen Zhao , Rongbo Lin , Nan-Feng Fan , Yigui Chen , Xiaofeng Li , Peicheng Lin , Wujin Chen , Wenzheng Fang , Jinfeng Zhu , Hui Li , Jie Liu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT02845908
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 4041)
DOI
10.1200/JCO.2021.39.15_suppl.4041
Abstract #
4041
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Safety and efficacy of intraperitoneal paclitaxel plus systemic FOLFOX for gastric cancer with peritoneal metastasis: Phase I results.
First Author: So Hyun Kang
Poster
2019 ASCO Annual Meeting
POF (paclitaxel plus FOLFOX) versus IP PAC (intraperitoneal paclitaxel plus FOLFOX) versus FOLFOX as a first-line treatment in advanced gastric cancer (AGC): Update from a multicenter, randomized phase II trial, FNF-004 trial.
First Author: Rongbo Lin
Poster
2017 Gastrointestinal Cancers Symposium
A phase II Study of FOLFOX versus POF (paclitaxel plus FOLFOX) versus IP PAC (intraperitoneal paclitaxel) plus FOLFOX as a first-line treatment in advanced gastric cancer (AGC): A feasibility analysis.
First Author: Rongbo Lin
Poster
2015 ASCO Annual Meeting
FOLFOX alone or combined to rilotumumab or panitumumab as first-line treatment in patients (pts) with advanced gastroesophageal adenocarcinoma (AGEA): An open-label, randomized phase II trial (PRODIGE 17 ACCORD 20 MEGA).
First Author: David Malka